Evidence map›Paper›PMID 35783822›Full record

ArticleFrontiers in cardiovascular medicine2022

Colchicine for the Treatment of Cardiac Injury in Hospitalized Patients With Coronavirus Disease-19.

Amir Rabbani, Asim Rafique, Xiaoyan Wang, Danielle Campbell, Daniel Wang, Nicholas Brownell, Kenia Capdevilla, Victoria Garabedian, Sandra Chaparro, Raul Herrera and 2 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04355143 (Randomized, Open-Label, Controlled Trial of Colchicine to Reduce Cardiac Injury in Hospitalized COVID-19), which is not on this map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04355143 phase2completednot on this map

Randomized, Open-Label, Controlled Trial of Colchicine to Reduce Cardiac Injury in Hospitalized COVID-19 (Coronavirus Disease 2019) Patients (COLHEART-19)

TypeinterventionalSponsorUniversity of California, Los AngelesRan2020 to 2021Enrolled93ConditionsCOVID-19ArmsColchicine Tablets, Current care per UCLA treating physicians
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Amir RabbaniDivision of Cardiology, University of California, Los Angeles, Los Angeles, CA, United States.
Asim RafiqueDivision of Cardiology, University of California, Los Angeles, Los Angeles, CA, United States.
Xiaoyan WangDivision of General Internal Medicine and Health Services Research, University of California, Los Angeles, Los Angeles, CA, United States.
Danielle CampbellDivision of Cardiology, University of California, Los Angeles, Los Angeles, CA, United States.
Daniel WangDivision of Cardiology, University of California, Los Angeles, Los Angeles, CA, United States.
Nicholas BrownellDivision of Cardiology, University of California, Los Angeles, Los Angeles, CA, United States.
Kenia CapdevillaMiami Cardiac and Vascular Institute, Baptist Health South Florida, Miami, FL, United States.
Victoria GarabedianMiami Cardiac and Vascular Institute, Baptist Health South Florida, Miami, FL, United States.
Sandra ChaparroMiami Cardiac and Vascular Institute, Baptist Health South Florida, Miami, FL, United States.
Raul HerreraMiami Cardiac and Vascular Institute, Baptist Health South Florida, Miami, FL, United States.
Rushi V ParikhDivision of Cardiology, University of California, Los Angeles, Los Angeles, CA, United States.
Reza ArdehaliDivision of Cardiology, University of California, Los Angeles, Los Angeles, CA, United States.
University of California, Los Angeles · USBaptist Health South Florida · US

Funding

CARDIOVASCULAR SCIENTIST TRAINING PROGRAMT32HL007895 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SHIVKUMAR, KALYANAM, WATSON, KAROL E · 1998 to 2023
$9.2M
NHLBI NIH HHS T32 HL007895
6 · The paper itself

Abstract

Introduction: The impact of colchicine on hospitalized patients with Coronavirus disease-19 (COVID-19) related cardiac injury is unknown. Materials and Methods: In this multicenter randomized controlled open-label clinical trial, we randomized hospitalized adult patients with documented COVID-19 and evidence of cardiac injury in a 1:1 ratio to either colchicine 0.6 mg po twice daily for 30 days plus standard of care or standard of care alone. Cardiac injury was defined as elevated cardiac biomarkers, new arrhythmia, new/worsened left ventricular dysfunction, or new pericardial effusion. The primary endpoint was the composite of all-cause mortality, need for mechanical ventilation, or need for mechanical circulatory support (MCS) at 90 days. Key secondary endpoints included the individual components of the primary endpoint and change in and at least 2-grade reduction in the World Health Organization (WHO) Ordinal Scale at 30 days. The trial is registered with clinicaltrials.gov (NCT04355143). Results: We enrolled 93 patients, 48 patients in the colchicine arm and 45 in the control arm. There was no significant difference in the primary outcome between the colchicine and control arms (19 vs. 15%, Conclusion: Patients hospitalized with COVID-19 and evidence of cardiac injury did not benefit from colchicine therapy.

Indexed as

cardiac injurycolchicineCOVID-19inflammasomemyocarditis

Identifiers

PMID35783822
PMCPMC9247184
OpenAlexW4283018608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.